Dihydropyrimidine dehydrogenase (DPD) polymorphisms knocking on the door.

Area of Science:

• Pharmacogenomics
• Oncology
• Clinical Chemistry

Background:

• Fluoropyrimidines are widely used chemotherapy agents.
• Dihydropyrimidine dehydrogenase (DPYD) enzyme metabolizes fluoropyrimidines.
• DPYD gene variations can lead to reduced enzyme activity and increased toxicity.

Purpose of the Study:

• To highlight the importance of identifying DPYD gene polymorphisms.
• To discuss the benefits of personalized fluoropyrimidine treatment based on DPYD testing.
• To emphasize the potential for improved patient outcomes and cost-effectiveness.

Main Methods:

• Review of current literature on DPYD gene polymorphisms and fluoropyrimidine toxicity.
• Analysis of the clinical implications of DPYD variant identification.
• Discussion of cost-effectiveness of DPYD-guided treatment adjustments.

Main Results:

• DPYD gene polymorphisms are significant predictors of fluoropyrimidine-associated toxicity.
• Dose adjustments based on DPYD testing can mitigate severe adverse events.
• Personalized treatment strategies enhance patient safety and reduce healthcare expenditure.

Conclusions:

• Identifying DPYD variants is crucial for safe and effective fluoropyrimidine chemotherapy.
• Personalized dosing strategies based on DPYD genotyping offer significant clinical and economic benefits.
• Implementing DPYD variant screening can optimize cancer treatment outcomes.